Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

This study found that inhibiting neurosteroidogenesis affected GABA A receptor-mediated synaptic inhibition in immature rats but not in adults, suggesting age-dependent modulation of synaptic strength in the spinal dorsal horn.

This report describes five cases where sudden akathisia occurred in female patients with bipolar disorder after a ziprasidone dose reduction, emphasizing potential unexpected side effects of second-generation antipsychotics.

In a testosterone-induced BPH rat model, this study found that ursolic acid treatment significantly reduced prostate weight and hormone levels, suggesting it may inhibit BPH development.

In this report, a 58-year-old woman with ocular myasthenia gravis experienced complete resolution of symptoms and hair regrowth after six months of treatment with the JAK inhibitor baricitinib, highlighting a potential new therapeutic approach for this condition.

This study found that baricitinib is effective for treating severe alopecia areata, with significant hair regrowth observed by the third month of therapy and continued improvement by month 12, while adverse events were mainly mild.

In this animal study, agmatine exhibited a protective effect against seizures related to hormone fluctuations, with results suggesting that its anticonvulsant properties may involve interactions with central neurosteroids in female rats experiencing progesterone withdrawal.

At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.

Neurosteroids in the brain can increase or decrease seizure risk in mice.

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This study reports that 4-(alkylthio)- and 4-(arylthio)-benzonitriles showed moderate sebum reduction as androgen receptor antagonists when applied topically in a validated animal model.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This study identified compounds from Laportea bulbifera with potential inhibitory effects on human steroid 5α-reductase 2, suggesting their application in treating benign prostatic hyperplasia.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

In this case report, a 60-year-old woman with alopecia areata and type 1 diabetes experienced hypoglycemic seizures after starting baricitinib, though reducing the dose alleviated these episodes; the study highlights the need for caution and glucose monitoring when using JAK inhibitors in at-risk patients.

This study found that betulinic acid inhibits hepatitis C virus replication by suppressing the NF-κB- and ERK1/2-mediated COX-2 pathway, suggesting its potential as a therapeutic supplement.

This study found that GD-23, a dipeptide ligand of TSPO, exhibited an anxiolytic effect in the elevated plus maze test, which was inhibited by selective neurosteroid synthesis inhibitors, suggesting a neurosteroidogenic mechanism.

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

Inhibiting certain enzymes made female rats more sensitive to low-level pain.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study demonstrated that certain metal salts can bind to sodium valproate and discussed the potential link to hair loss in patients treated for epilepsy.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.

This review discusses the medicinal properties of Alpinia zerumbet Roxb. and highlights its potential for further research, but provides no new clinical results.

This study found that abietic acid from pine resin more effectively inhibits testosterone 5α-reductase than several plant extracts, suggesting potential for treating androgen-dependent diseases.